Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL)...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Blood
Huvudupphovsmän: Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan A., Blum, Kristie A., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Shaw, Yun, Bilotti, Elizabeth, Zhou, Cathy, James, Danelle F., O'Brien, Susan
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2015
Ämnen:
Clinical Trials and Observations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4400288/
https://ncbi.nlm.nih.gov/pubmed/25700432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-10-606038
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk